Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRUG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$28.83+0.2%$35.81$0.93▼$79.02$203.08M-5.5819,894 shs23,468 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences+0.24%-10.02%-20.47%-25.87%+2,263.11%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRUGBright Minds Biosciences2.7149 of 5 stars3.63.00.00.03.82.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRUGBright Minds Biosciences 3.20Buy$84.33192.52% UpsideCurrent Analyst Ratings BreakdownLatest DRUG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/19/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.00 ➝ $85.001/23/2025DRUGBright Minds BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$93.00(Data available from 4/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRUGBright Minds BiosciencesN/AN/AN/AN/A$5.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRUGBright Minds Biosciences-$2.06M-$0.17N/AN/AN/AN/A-5.85%-5.68%5/21/2025 (Estimated)Latest DRUG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/13/2025Q1 2025DRUGBright Minds Biosciences-$0.23$0.01+$0.24$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRUGBright Minds BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRUGBright Minds BiosciencesN/A126.0111.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRUGBright Minds Biosciences40.52%Insider OwnershipCompanyInsider OwnershipDRUGBright Minds Biosciences42.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableDRUG HeadlinesRecent News About These CompaniesSpringhill Fund Asset Management HK Co Ltd Purchases Shares of 60,648 Bright Minds Biosciences Inc. (NASDAQ:DRUG)April 8, 2025 | marketbeat.comAtika Capital Management LLC Takes Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)April 8, 2025 | marketbeat.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Short Interest UpdateMarch 20, 2025 | marketbeat.comCantor Fitzgerald Has Weak Forecast for DRUG FY2025 EarningsMarch 17, 2025 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Trading Down 0.8% - Here's WhyMarch 15, 2025 | marketbeat.comBright Minds Biosciences expands Scientific Advisory BoardMarch 4, 2025 | markets.businessinsider.comBright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy ResearchMarch 4, 2025 | markets.businessinsider.comBright Minds Biosciences to Participate at Three Healthcare Conferences in MarchFebruary 24, 2025 | manilatimes.netBright Minds Biosciences (DRUG) Receives a New Rating from Piper SandlerFebruary 14, 2025 | markets.businessinsider.comBiotechs on the Brink: 2 Stocks With Huge Potential (DRUG)February 14, 2025 | marketbeat.comWhen (DRUG) Moves Investors should ListenFebruary 12, 2025 | news.stocktradersdaily.comBright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101January 26, 2025 | seekingalpha.comPiper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight RecommendationJanuary 24, 2025 | msn.comBright Minds Biosciences initiated with an Overweight at Piper SandlerJanuary 23, 2025 | markets.businessinsider.comYasmeen Rahimi’s Buy Rating on Bright Minds Biosciences Driven by Promising Potential of BMB-101 for Epilepsy TreatmentJanuary 23, 2025 | markets.businessinsider.comPiper Sandler sets $93 target for Bright Minds Biosciences stockJanuary 23, 2025 | msn.comLearn to Evaluate (DRUG) using the ChartsJanuary 22, 2025 | news.stocktradersdaily.comCantor Fitzgerald Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight RecommendationJanuary 11, 2025 | msn.comHC Wainwright & Co. Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy RecommendationJanuary 11, 2025 | msn.comBright Minds Biosciences initiated with a Buy at H.C. WainwrightJanuary 10, 2025 | markets.businessinsider.comBright Minds Biosciences initiated with a Buy at H.C. WainwrightJanuary 10, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingIs Viking Therapeutics the Next Blockbuster GLP-1 Stock?By Jea Yu | March 18, 2025View Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?D-Wave: Multiple Use Cases Emerge Following Quantum SupremacyBy Nathan Reiff | April 1, 2025View D-Wave: Multiple Use Cases Emerge Following Quantum SupremacyCan Solid Biosciences Challenge Sarepta in the DMD Market?By Leo Miller | April 8, 2025View Can Solid Biosciences Challenge Sarepta in the DMD Market?DRUG Company DescriptionsBright Minds Biosciences NASDAQ:DRUG$28.83 +0.07 (+0.24%) Closing price 04/11/2025 04:00 PM EasternExtended Trading$30.86 +2.03 (+7.04%) As of 04/11/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan is a Buy, if You Can Handle The Volatility Rocket Lab Stock: Weathering the Storm, Time for a Comeback? United States Steel's Crash: An Unmissable Buying Opportunity Micron Tumbles on Tariff Threat: Risk/Reward Outlook Improves Is Archer Aviation’s Stock Price Dip a Gift? Marvell Gets Tariff Lifeline But Expect More Volatility Snowflake Boosts Growth by Doubling Down on AI Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
